Literature DB >> 22609296

Biliary atresia.

Ulrich Baumann1, Benno Ure.   

Abstract

Biliary atresia is an obliterative cholangiopathy with progressive hepatobiliary disease, starting from the perinatal period. With a frequency of 1/15-18,000 live births, biliary atresia is the commonest cause of life-threatening liver disease in infants, and fatal if untreated. Prognosis is poor, unless early diagnosis is followed by surgical treatment. Clinical aspect, liver function tests, scintigraphy, histology, and increasingly, ultrasound techniques and endoscopic retrograde cholangiography are being used to discriminate other causes of neonatal cholestasis. Ten-year survival of children with biliary atresia, including those transplanted for end-stage liver disease, is up to 90%. Prognosis and outcome are largely dependent on early diagnosis and expert surgical management.
Copyright © 2012 Elsevier Masson SAS. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22609296     DOI: 10.1016/j.clinre.2012.03.017

Source DB:  PubMed          Journal:  Clin Res Hepatol Gastroenterol        ISSN: 2210-7401            Impact factor:   2.947


  10 in total

1.  The correlation between plasma cytokine levels in jaundice-free children with biliary atresia.

Authors:  Zhi-Hong Jian; Li-Ching Wang; Chieh-Chung Lin; Jiaan-Der Wang
Journal:  World J Pediatr       Date:  2015-04-06       Impact factor: 2.764

2.  Imaging prediction with ultrasound and MRI of long-term medical outcome in native liver survivor patients with biliary atresia after kasai portoenterostomy: a pilot study.

Authors:  Martina Caruso; Fabiola Di Dato; Carmine Mollica; Gianfranco Vallone; Valeria Romeo; Raffaele Liuzzi; Pier Paolo Mainenti; Mario Petretta; Raffaele Iorio; Arturo Brunetti; Simone Maurea
Journal:  Abdom Radiol (NY)       Date:  2021-02-02

3.  Clinical and pathological features of patients with biliary atresia who survived for more than 5 years with native liver.

Authors:  Song Sun; Shan Zheng; Xuexin Lu; Gong Chen; Yangyang Ma; Lian Chen; Kuiran Dong
Journal:  Pediatr Surg Int       Date:  2018-02-09       Impact factor: 1.827

4.  Contribution of acoustic radiation force impulse (ARFI) elastography to the ultrasound diagnosis of biliary atresia.

Authors:  Sylviane Hanquinet; Delphine S Courvoisier; Anne-Laure Rougemont; Amira Dhouib; Laura Rubbia-Brandt; Barbara E Wildhaber; Laura Merlini; Valerie A McLin; Mehrak Anooshiravani
Journal:  Pediatr Radiol       Date:  2015-05-06

5.  Gene expression profiling of extrahepatic ducts in children with biliary atresia.

Authors:  Jiang Wang; Wei Wang; Rui Dong; Rui Zhao; Zhu Jin; Wenjun Shen; Shan Zheng
Journal:  Int J Clin Exp Med       Date:  2015-04-15

6.  Identification of the plasma metabolomics as early diagnostic markers between biliary atresia and neonatal hepatitis syndrome.

Authors:  Dongying Zhao; Lianshu Han; Zhengjuan He; Jun Zhang; Yongjun Zhang
Journal:  PLoS One       Date:  2014-01-08       Impact factor: 3.240

7.  Suppressing microRNA-29c promotes biliary atresia-related fibrosis by targeting DNMT3A and DNMT3B.

Authors:  Jian-Yao Wang; Hao Cheng; Hong-Yan Zhang; Yong-Qin Ye; Qi Feng; Zi-Min Chen; Yue-Lan Zheng; Zhou-Guang Wu; Bin Wang; Jun Yao
Journal:  Cell Mol Biol Lett       Date:  2019-03-11       Impact factor: 5.787

8.  Long-term prophylactic intravenous antibiotics after Kasai portoenterostomy for biliary atresia do not reduce the risks of post-operative cholangitis, a retrospective study.

Authors:  Xi-Si Guan; Qiu-Ming He; Wei Zhong; Jia-Kang Yu; Zhe Wang
Journal:  Transl Pediatr       Date:  2021-08

9.  Ultrasonographic findings of type IIIa biliary atresia.

Authors:  Seung-Seob Kim; Myung-Joon Kim; Mi-Jung Lee; Choon-Sik Yoon; Seok Joo Han; Hong Koh
Journal:  Ultrasonography       Date:  2014-06-10

10.  Direct bilirubin levels observed in prolonged neonatal jaundice: a retrospective cohort study.

Authors:  Joshua Mark Hodgson; Vivienne Hazel van Someren; Colette Smith; Atul Goyale
Journal:  BMJ Paediatr Open       Date:  2018-02-24
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.